1. Executive Summary (Confidence: High)

Santo Holding, alongside the Strüngmann family office Athos KG, manages one of the world’s most successful healthcare-driven fortunes, estimated at $30 billion. Founded by identical twin brothers Andreas (a medical doctor) and Thomas (a business expert), the family’s wealth was built through the 1986 founding of Hexal AG and its subsequent $7.5 billion sale to Novartis in 2005. Since then, Santo has operated as a "Patient Capital" powerhouse, emphasizing long-term entrepreneurial success over short-term returns. Their 2008 seed investment of €136.5 million in BioNTech is legendary, resulting in a 43.5% stake worth billions following the success of the COVID-19 mRNA vaccine. Today, Santo is a pillar of the global longevity and biotech ecosystem, backing high-potential startups like AAVantgarde Bio and Formycon that address severe unmet medical needs in aging and rare diseases.